水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效观察

水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效观察孙燕燕;郭英;季伟
【期刊名称】《中国医院用药评价与分析》
【年(卷),期】2017(017)012
【摘要】OBJECTIVE: To probe into the clinical efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis
B .METHODS:72 patients with liver cirrhosis of hepatitis B admitted into Ningxia People 's Hospital from Jan.2016 to Jan.2017 were selected and divided into observation group and control group via random number table , with 36 cases in each .The control group was treated with entecavir , while the observation group was given silibinin based on the control group .The liver function indicators , liver fibrosis indicators and incidence of adverse drug reactions of two groups were observed .RESULTS: After treatment , levels of alanine aminotransferase , prothrombin time , serum total bilirubin and albumin of two groups were better than those of before treatment , and the observation group was better than the control group , with statistical significance ( P <0.05 ) .After treatment, the hyaluronic acid , type Ⅳprocollagen and type Ⅲprocollagen levels were better than those of before treatment , and the observation group was better than the control group , with statistical significance(P<0.05).The incidence of adverse drug reactions of observation group was 11.12％( 4/36 ) , significantly lower than that of control group [ 30.58％( 11/36 ) ] , with
statistical significance ( P<0.05 ) .CONCLUSIONS:The efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B is remarkable , which can effectively improve levels of liver function indicators and liver fibrosis indicators with fewer adverse drug reactions .%目的:探讨水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的临床疗效.方法:选取2016年1月—2017年1月宁夏回族自治区人民医院收治的乙型病毒性肝炎肝硬化患者72例作为研究对象,以随机数字表法分为观察组和对照组,每组36例.对照组患者给予恩替卡韦,观察组患者在对照组的基础上加用水飞蓟宾.观察两组患者的肝功能、肝纤维化指标水平和不良反应发生情况.结果:治疗后,两组患者丙氨酸氨基转移酶、凝血酶原时间、血清总胆红素和白蛋白水平明显优于治疗前,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);两组患者透明质酸、Ⅳ型胶原和Ⅲ型前胶原水平明显优于治疗前,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);观察组患者不良反应发生率为11.12％(4/36),明显低于对照组的30.58％(11/36),差异有统计学意义(P<0.05).结论:水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效显著,可有效改善患者肝功能、肝纤维化指标水平,且不良反应少.
【总页数】3页(P1636-1637,1640)
【作者】孙燕燕;郭英;季伟
【作者单位】宁夏回族自治区人民医院/西北民族大学第一附属医院感染科,宁夏银川 750001;宁夏回族自治区人民医院/西北民族大学第一附属医院感染科,宁夏银川750001;宁夏回族自治区人民医院/西北民族大学第一附属医院感染科,宁夏银川750001
【正文语种】中文
【中图分类】R975+.5
【相关文献】
1.恩替卡韦联合水飞蓟宾药物治疗乙型病毒性肝炎肝硬化效果分析 [J], 温庆杰
2.恩替卡韦联合水飞蓟宾药物治疗乙型病毒性肝炎肝硬化效果分析 [J], 温庆杰
3.恩替卡韦联合水飞蓟宾治疗乙型肝炎肝硬化的效果 [J], 杨微娜
4.水飞蓟宾联合恩替卡韦治疗老年乙肝肝硬化患者的价值分析 [J], 刘同博
5.恩替卡韦联合水飞蓟宾药物治疗乙型病毒性肝炎肝硬化的临床效果观察 [J], 许佳音
因版权原因，仅展示原文概要，查看原文内容请购买。